News of Note - February 28, 2023

BULL BEAR BRES|NAHAN

Tuesday, February 28, 2023

---> 09:46

Something I often ponder, as I weed through press releases, how driven am I by the 'news' cycle versus organic work - something to consider, that..

😊

Br. -john

p.s. on that note - elevating one piece of news as it has the potential to truly ripple through the healthcare space (neuro/cns in particular) 👇👇👇

Stat

FDA’s Billy Dunn, key figure in approval of Aduhelm, to leave agency

Billy Dunn, who presided over the polarizing approval of the Alzheimer’s disease treatment Aduhelm, is leaving the FDA after more than 15 years at the agency.
Dunn, 53, is retiring from the agency to “explore other opportunities,” according to an internal FDA email sent Monday.
Teresa Buracchio, deputy director of the office of neuroscience, has been named acting director to replace Dunn, according to Stein’s email.

*PRESS RELEASES*

BAYN GY

Bayer

Release

https://www.bayer.com/media/en-us/bayer-significant-growth-in-sales-and-earnings/

Hub

https://www.bayer.com/en/investors/fyq4-2022-results

Presentation

https://www.bayer.com/sites/default/files/2023-02/FY-Q4_2022_ConferenceCall_2023-02-28_Presentation_charts.pdf

Webcast

https://edge.media-server.com/mmc/p/gv72yweh

LAMOR FH

Lamor Corporation

Financial Statements Release for 2022: A great year of growth behind - growth investments in line with the strategy continue

ANORA FH

Anora

Financial Statement Bulletin January–December 2022: Exceptionally high input costs decreased profitability – net sales for 2022 grew 5.7%

RAIVV FH

Raisio

Sells its fish feed business to Finnforel

ELEKTA SS

Elekta

Receives FDA 510(k) clearance for advanced radiotherapy motion management using Elekta Unity MR-Linac

BIOAB SS

BioArctic

Hires Anders Martin-Löf as new CFO

MOLN SW

Molecular Partners

Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform

BIOAB SS

BioArctic

Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration

KYMR

Kymera

8-K

On February 27, 2023 Kymera Therapeutics, Inc. (the “Company”) announced that Elaine Caughey, its Chief Business Officer, will be departing the Company for personal family reasons effective as of April 10, 2023.

OXY

Occidental

Release

https://www.oxy.com/globalassets/documents/investors/quarterly-earnings/oxy4q22earningspressrelease.pdf

Presentation

https://www.oxy.com/globalassets/documents/investors/quarterly-earnings/oxy4q22conferencecallslides.pdf

Webcast

https://edge.media-server.com/mmc/p/pteryc4k

RVMD

Revolution Medicines

Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

BMRN